CANTOS has previously demonstrated that IL‐1b inhibition with canakinumab, compared with placebo, lowers the inflammatory biomarkers CRP and IL6 by 35 to 45 percent and significantly reduces rates of several clinical disorders associated with aging, including cardiovascular events, lung cancers, gout, anemia, and large joint osteoarthritis (Ferrucci & Fabbri, 2018; Jenny, 2012; Ridker et al., 2017; Ridker, MacFadyen, et al., 2017; Vallurupalli et al., 2020). Here, IL1B is linked to gout.